Update on pythiosis immunobiology and immunotherapy

Table 2 Review of human pythiosis cases reported in the literature when treated with immunotherapy

n	Lesions	Adjunctive therapy	Immunotherapy type2, doses	Outcome	Ref.
1	Vascular	ATM, surgery	SA, 2 doses at 14-d intervals	C	[19]
8	Vascular	Surgery/amputation, ATF	SA, 21 doses at 14-d intervals	C (50%)	[18]
1	Vascular	Above-knee amputation	SA, Nr	C	[116]
1	Vascular	ATM, limb amputation	SA, Nr	D	[117]
1	Ocular	ATM, enucleation	Nr	D	[118]
1	Vascular	Above-knee amputation	Nr	C	[119]
1	Vascular	ATM, above-knee amputations	Nr	C	[120]
1	Vascular	ATM, above-the-knee-amputation	Nr, 4 doses at 7-d intervals	C	[95]
1	Vascular/disseminated	ATM	SA, 2 doses at 7-d intervals	D	[121]
3	Ocular	ATM, surgery	Nr, 3 doses	C (66%)	[122]

¹At least;

²Manufacturing process for immunotherapy. Nr: Not reported; SA: Soluble antigens; C: Cured; D: Died; ATM: Antimicrobials; ATF: Antifungals.